©The Author(s) 2016.
World J Gastrointest Pathophysiol. Feb 15, 2016; 7(1): 27-37
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.27
Published online Feb 15, 2016. doi: 10.4291/wjgp.v7.i1.27
Table 1 Current biomarkers and their utility in inflammatory bowel disease management[12]
| Application | Biomarker | Utility |
| Diagnosis of IBD | Fecal calprotectin[69] | Sensitivity: 89%-98%, specificity: 81%-91% |
| Fecal lactoferrin[70] | Sensitivity: 80%, specificity: 82% | |
| Fecal 100A12[71] (differentiating from IBS) | Sensitivity: 86%, specificity: 96% | |
| CRP[72-74] | Sensitivity: Approximately equal 100% in CD, approximately equal 50% in UC poor specificity | |
| Distinguishing UC and CD | ASCA[75] | Sensitivity: 40%-50%, specificity: > 90% in CD |
| pANCA[75] | Sensitivity: 57%, specificity: 92% | |
| Escherichia coli antibodies (Anti-OmpC, Anti-I2, Anti-CBir1)[76] | Sensitivity: 18%-55%, specificity: 76%-93%[76] | |
| Marker of disease activity | Fecal lactoferrin[77,78] | Sensitivity: 66%-80% |
| Specificity: 60%-100% | ||
| Fecal calprotectin[77,78] | Sensitivity: 70%-100% | |
| Specificity: 44%-100% | ||
| CRP[78] | Sensitivity: 48% | |
| Specificity: 91% | ||
| Assessing mucosal healing | Fecal calprotectin | Several studies demonstrate significant reduction in biomarker in the presence of mucosal healing with treatment |
| Predicting disease course | Fecal lactoferrin[77] | May be associated with complications including; structuring or fistulising disease, and small bowel disease pANCA may predict aggressive UC and pouchitis following surgery[79] |
| ASCA | ||
| pANCA Anti-I2, Anti-OmpC[12] | ||
| Predicting Relapse within 12 mo | Fecal calprotectin[80,81] | Sensitivity: 69%-90% |
| Specificity: 69%-82% | ||
| Positive predictive value: 81%/87% (UC/CD) | ||
| Negative predictive value: 90%/43% (UC/CD) | ||
| Fecal lactoferrin[81] | Sensitivity: 62% | |
| Specificity: 65% | ||
| Predicting therapeutic response | pANCA[82] | Conflicting reports, possible lower response rate to infliximab in patients with a positive serology |
| Anti-I2[83] | 94% responded to fecal diversion |
- Citation: Chan PP, Wasinger VC, Leong RW. Current application of proteomics in biomarker discovery for inflammatory bowel disease. World J Gastrointest Pathophysiol 2016; 7(1): 27-37
- URL: https://www.wjgnet.com/2150-5330/full/v7/i1/27.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v7.i1.27